Clinicopathological characteristics of giant cell tumor of bone and…
Osteoclast-rich bone lesions present overlapping clinical and radiological features, while their biological behaviors and treatment protocols differ greatly, posing challenges for differential diagnosis. H3.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Survival Outcomes With Cadonilimab Versus PD-(L)1 Therapy in…
The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk-benefit profile for patients with low PD-L1 expression remains unclear in front-line treatment of HER2-negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD-(L)1 therapy. The first PD-1/CTLA-4 bispecific antibody (BsAb), cadonilimab, has been approved, but it is unknown if it can extend the PD-(L)1 regimen to lower PD-L1 patients.
Promising but preliminaryReal-world treatment patterns and outcomes in metastatic clear cell…
Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized.
Promising but preliminaryTreatment of acute myeloid leukemia with inv(3) or t(3;3)
AML with inv(3)(q21. 3q26.
Promising but preliminaryRobotic assistance in total hip arthroplasty
This review examined whether robotic assistance alters postoperative leg-length discrepancy (LLD), acetabular cup orientation, or early hip-specific outcomes relative to conventional total hip arthroplasty (THA). We searched PubMed and Web of Science through May 2026 for comparative English-language reports.